On August 6, 2026, a trial update was recorded for secretin under study identifier NCT06276764. The study, titled "The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)," is a registry involving secretin, an approved compound.
The current status of this study is listed as enrolling by invitation. No phase was specified for this registry study in the available record.
This update reflects the recruitment status of the LINFU U.S. Registry as of the date listed. No outcomes, efficacy data, or safety findings were included in this update. The record does not state any results at this time.
Readers should note that a registry enrolling by invitation typically restricts participation to a specific pre-identified patient population rather than open public enrollment. Further details about study design, eligibility, and objectives can be found in the official trial listing.
For additional context on secretin, including its approved regulatory status and general background, readers can consult the compound overview.